DILI prediction in drug development: present and future.

Area of Science:

• Drug-induced liver injury
• Immunology
• Biomarker discovery

Background:

• Idiosyncratic drug-induced liver injury (iDILI) poses significant risks to patient health and drug development.
• Current screening methods for iDILI risk are insufficient.
• Understanding the underlying mechanisms of iDILI is crucial for developing effective predictive tools.

Purpose of the Study:

• To review the general mechanism of iDILI.
• To evaluate current methods for screening iDILI risk.
• To explore the potential of new biomarkers for predicting iDILI.

Main Methods:

• Review of existing literature on iDILI mechanisms and screening.
• Exploration of immune system involvement in iDILI pathogenesis.
• Identification of potential biomarkers based on cellular responses.

Main Results:

• iDILI is primarily driven by adaptive immune responses, specifically CD8+ cytotoxic T cells, rather than direct drug toxicity.
• In vitro cytotoxicity assays do not accurately reflect iDILI mechanisms.
• Innate immune responses, including antigen-presenting cell activation and hepatocyte-released damage-associated molecular pattern molecules (DAMPs), are critical for initiating iDILI.

Conclusions:

• Biomarkers for iDILI risk should be based on the immune-mediated mechanism of injury.
• Hepatocyte responses, release of DAMPs (especially in extracellular vesicles), and antigen-presenting cell activation are promising candidates for novel iDILI biomarkers.
• Developing mechanism-based biomarkers will enhance the safety of drug development and reduce patient morbidity.